What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many ...

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

The market expects 10x Genomics (TXG) to deliver a year-over-year increase ... This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor ...

Serge Saxonov, the Chief Executive Officer of $TXG, sold 7,942 shares of the company on 02-28-2025 for an estimated $84,393. We received data on the trade from a ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

10x Genomics has set its FY 2025 guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link. 10x Genomics (NASDAQ:TXG – Get Free Report ...

B iotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million. On the other hand, the company’s full-year revenue guidance of $620 ...

On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of $(0.30). The single-cell and spatial biology company reported quarterly ...

2024 marks the sixth consecutive year production guidance has been achieved Toronto, Ontario--(Newsfile Corp. - January 8, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) ...